LesinskiLab

Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity Cole et al. report that adoptively transferred, tumor-specific Th17 cells engage host B cells and drive B cell proliferation and differentiation. These Th17 cells require B cells for sustained immunit...

🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back.
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!

Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma - PubMed These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant pre-...

Check out our new paper in Hepatology on how myeloid cells limit immunotherapy in preclinical cholangiocarcinoma models!
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!

pubmed.ncbi.nlm.nih.gov/40590857/

Neoantigens drive adoptively transferred CD8 T cells to long-lived effectors mediated by lymph node trafficking Adoptive transfer of neoantigen-reactive T lymphocytes mediates potent responses against solid tumors in patients while often limiting toxicity to normal tissues; however, the mechanisms governing the...

Cool pre-print alert! insight into how neoAg alter trafficking of adoptively transferred T cells! Proud to be part of this stellar collaboration with @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu

www.biorxiv.org/content/10.1...

On April 23, participate in 5 topic-driven sessions at SITC’s ACI: A Focus on Gastrointestinal Cancers program! Gain in-depth education on all aspects of clinical implementation of IO for GI cancers.

Advance your clinical practice and earn free CME: ow.ly/SPaR50VEJbg
@lesinskilab.bsky.social 🧪

High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Signatures Between Primary and Metastatic Pancreatic Ductal Adenocarcinoma Our understanding of the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) primarily stems from murine models or primary patient tumors. While metastatic tumors have generally less ...

www.biorxiv.org/content/10.1...
Excited to share our preprint on comparing Human Primary and metastatic #pancreaticcancer!!!

Grateful to #kevinvanderjeught for the opportunity to visit the powerhouse #GIoncology program at #umiami Sylvester cancer center @drjashdatta.bsky.social #nipunmerchant

So very proud of our newly minted Dr. Maggie Phillips! @winshipatemory.bsky.social
She showcased her amazing translational oncology experience in today’s public defense!

Inspiring (as always) @cholangiocarcinoma.bsky.social annual meeting comes to a close. Our @winshipatemory.bsky.social team returns motivated by survivors, patients and caregivers to make a difference! @megen-w.bsky.social @chrystalpaulos.bsky.social

Tremendous talk by Dr. Kailey Oppat @winshipatemory.bsky.social on #FGFR and #IDH interaction with #immune signatures in #cholangiocarcinoma via collab w #carisls @cholangiocarcinoma.bsky.social annual meeting!

XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial We conducted a phase Ib/II clinical trial to evaluate the safety, feasibility, and clinical activity of combining pembrolizumab (anti-PD-1) with XL888 (Hsp90 inhibitor) in patients with advanced co...

Proud to report our new manuscript describing clinical
Trial results of dual Hsp90/PD1 inhibition in #colorectalcancer. @winship Full article: XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial www.tandfonline.com/doi/full/10....

Very well done article on pancreatic cancer @wsj.com highlighting hope in a devastating disease. Adding the note that fundamental discoveries related to Kras were derived from NIH funding supported by tax dollars well spent.

@immunegirl.bsky.social teaching us all a thing or two about TCRs! @sitcancer.bsky.social winter school master class!

Stellar talk by @zach-buchwald.bsky.social @winshipatemory.bsky.social at SITC winter school!

@chrystalpaulos.bsky.social @winshipatemory.bsky.social knocks it out of the park @sitcancer.bsky.social winter school on the power of CD4 T cells!

Dr. Yina Huang brings the house down with her AMAZING talk on harnessing synthetic biology to augment next generation cell therapy for cancer patients at Winter School @sitcancer.bsky.social 💥

We’re thrilled to welcome Dr. Perrine Verdys and Shawez Khan from Denmark and Moldir Konysbekova from Kazakhstan to our 2025 Cancer Immunotherapy Winter School program.

Thanks to all the attendees that made the trip to Austin!
#CIWS2025

Congrats to my brilliant collaborator and friend @chrystalpaulos.bsky.social in this important leadership role!

BREAKING NEWS: CDC orders mass retraction and revision of submitted research across all science and medicine journals. Banned terms must be scrubbed. Any unpublished manuscript mentioning certain topics, including gender and "LGBT," must be pulled or revised.

BREAKING NEWS: CDC orders mass retraction and revision of submitted research across all science and medicine journals. Banned terms must be scrubbed.

Goes beyond MMWR +other CDC pubs. Applies to research already submitted to top medical journals.

Take a look.
open.substack.com/pub/insideme...

Time is running out! Prospective post docs please apply to our event to learn about @winshipatemory.bsky.social

Apply at this link
brnw.ch/21wPrWk

Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine Nagaraju et al. have identified that paricalcitol (P) plus hydroxychloroquine (H) potentiates the efficacy of gemcitabine (G) in PDAC. GPH treatment induces ER stress and autophagy with M1 polarization and T cell activation. These findings in PDAC patient-derived data highlight the potential translational impact of GPH therapy in improving clinical outcomes.

Important lab bench to clinical trial study led by Bassel El-Rayes, MD and many other colleagues on a new combination chemo regimen in pancreatic cancer. Honored to collaborate in this effort!

www.cell.com/cell-reports...

Join us on March 13-14, 2025, for postdoctoral recruitment event at Winship! Network with mentors and postdocs, and explore Emory's research and career resources. 📅 Apply by January 10, 2025

🔗 Details & Application: brnw.ch/21wPrWk

#PostdocOpportunities #CancerResearch #WinshipResearch

We are accepting poster abstract submissions for our upcoming annual conference. This is an opportunity to present late-breaking results, ongoing research projects, and innovative work in cholangiocarcinoma research. Submit an abstract here: cholangiocarcinoma.org/annual-confe...

Entertaining debate on #TIL between Dr Betof-Warner and @chrystalpaulos.bsky.social #Bridge2024

Outstanding clinical presentation for neoadjuvant cutaneous squamous cell carcinoma by @winshipatemory.bsky.social Dr Michael Lowe #bridge24

Great talk by @jguerriero.bsky.social on macrophages at #Bridge24

T cell guru @chrystalpaulos.bsky.social talking B cells!?! Bridge#24 highlight

And the last debate! Dr Emens vs Dr Khlief ADC vs Bispecifics!

Round 2! The one and only @bernardafox.bsky.social vs Dr Igor Puzanov debating combo trials with agents that lack single agent activity #Bridge24

The great debate begins at #bridge24 Dr Tawbi vs Dr Hamid!

IT HAS STARTED! The 10th #Immunotherapy #Bridge2024 Prof. @PAscierto opens conf with a quick review of decade worth of meetings. Even thru #SarsCov2 this meeting never skipped a beat. Looking forward to 4 days of excellent talks & debates. @sitcancer.bsky.social #cancer #FinishCancer #NCI